<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2018-8-2-27-32</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-315</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Роль сатурационной трансперинеальной биопсии в диагностике рака предстательной железы в «эру» таргетной fusion-биопсии</article-title><trans-title-group xml:lang="en"><trans-title>The Role of Saturation Transperineal Biopsy in the Diagnosis of Prostate Cancer in the Era of Targeted Fusion Biopsies</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5071-0604</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кельн</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Keln</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры онкологии с курсом урологии, 625023, Тюмень, ул. Одесская, 54;</p><p>625000, Тюмень, ул. Барнаульская, 32;</p><p>625000, Тюмень, ул. Юрия Семовских, 8/1</p></bio><bio xml:lang="en"><p>Assistant Lecturer of the Department of Oncology with the Course of Urology, 54 Odesskaya str., Tyumen, 625023;</p><p>32 Barnaulskaya str., Tyumen, 625000;</p><p>8/1 Yuriy Semovskikh str., Tyumen, 625000</p></bio><email xlink:type="simple">artyom-keln@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8105-7233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зырянов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zyryanov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор,</p><p>620002, Екатеринбург, ул. Репина, 3</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor,</p><p>3 Repin str., Yekaterinburg, 620028</p></bio><email xlink:type="simple">zav1965@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зотов</surname><given-names>П. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Zotov</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, </p><p>625023, Тюмень, ул. Одесская, 54</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor,</p><p>54 Odesskaya str., Tyumen, 625023</p></bio><email xlink:type="simple">note72@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пономарев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ponomarev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>625000, Тюмень, ул. Барнаульская, 32;</p><p>заведующий отделением онкологии областного урологического центра, 625000, Тюмень, ул. Юрия Семовских, 8/1</p></bio><bio xml:lang="en"><p>32 Barnaulskaya str., Tyumen, 625000;</p><p>Head of the Department of Oncology,  8/1 Yuriy Semovskikh str., Tyumen, 625000</p></bio><email xlink:type="simple">ponomarevekb@gmail.com</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1238-4761</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суриков</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Surikov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>625000, Тюмень, ул. Барнаульская, 32;</p><p>врач-уролог отделения онкологии областного урологического центра, 625000, Тюмень, ул. Юрия Семовских, 8/1</p></bio><bio xml:lang="en"><p>32 Barnaulskaya str., Tyumen, 625000;</p><p>Urologist of the Department of Oncology, 8/1 Yuriy Semovskikh str., Tyumen, 625000</p></bio><email xlink:type="simple">surikov.a.s@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Знобищев</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Znobischev</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>625000, Тюмень, ул. Барнаульская, 32;</p><p>врач-уролог отделения онкологии областного урологического центра,  625000, Тюмень, ул. Юрия Семовских, 8/1</p></bio><bio xml:lang="en"><p>32 Barnaulskaya str., Tyumen, 625000;</p><p>Urologist of the Department of Oncology, 8/1 Yuriy Semovskikh str., Tyumen, 625000</p></bio><email xlink:type="simple">unksent@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Тюменский государственный медицинский университет;&#13;
ГАУ Тюменской области «Многопрофильный клинический медицинский центр «Медицинский город»;&#13;
Областной урологический центр АО «Медико-санитарная часть «Нефтяник»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tyumen State Medical University;&#13;
Multi-field Clinical Medical Centre “Medical city”;&#13;
Regional Urological Center of the Medical Care Unit “Neftyanik”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Тюменский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tyumen State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ГАУ Тюменской области «Многопрофильный клинический медицинский центр «Медицинский город»;&#13;
Областной урологический центр АО «Медико-санитарная часть «Нефтяник»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Multi-field Clinical Medical Centre “Medical city”;&#13;
3 Regional Urological Center of the Medical Care Unit “Neftyanik”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2018</year></pub-date><volume>8</volume><issue>2</issue><fpage>111</fpage><lpage>116</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кельн А.А., Зырянов А.В., Зотов П.Б., Пономарев А.В., Суриков А.С., Знобищев В.Г., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Кельн А.А., Зырянов А.В., Зотов П.Б., Пономарев А.В., Суриков А.С., Знобищев В.Г.</copyright-holder><copyright-holder xml:lang="en">Keln A.A., Zyryanov A.V., Zotov P.V., Ponomarev A.V., Surikov A.S., Znobischev V.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/315">https://www.surgonco.ru/jour/article/view/315</self-uri><abstract><sec><title>Введение</title><p>Введение. Одной из самых значимых проблем в диагностике рака предстательной железы является трудность выявления опухоли с помощью стандартных методов визуализации. В определенных клинических ситуациях сатурационная биопсия позволяет верифицировать объем и степень злокачественности опухоли, что может предопределить дальнейшую тактику лечения.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследован 81 пациент, средний возраст 63,5 ± 7,4 года, средний объем предстательной железы — 59 ± 24,2 см3 , средний уровень простатспецифического антигена 12,5 ± 8,9 нг/мл. Все пациенты прошли как минимум одну трансректальную биопсию. Средняя продолжительность сатурационной промежностной картирующей биопсии предстательной железы составила 25,2 ± 7,4 мин. Среднее число биоптатов — 25.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. По результатам cатурационной промежностной картирующей биопсии 34 пациентам (43,2 %) диагностирован рак предстательной железы. У всех пациентов с подтвержденной злокачественной патологией была выявлена ацинарная аденокарцинома. Опухоли с индексом Глисона 6 были выявлены у 22 (27,1 %) пациентов, с индексом 7 — у 9 (9,9 %) и 8 у 4 (4,9 %). Наиболее агрессивные типы опухоли (градация Глисона 7 и 8) соответствовали PIRADS 4 и 5. При градациях PIRADS 2,3 в 80 и 50 % соответственно встречались проявления аденомы предстательной железы без злокачественного проявления. У пациентов после радикальной простатэктомии изучены результаты планового послеоперационного морфологического заключения с данными биопсии. По результатам морфологического исследования установлено, что у 12 пациентов (80,0 %) опухоль располагалась в пределах капсулы предстательной железы и у 3 пациентов (20,0 %) не была ограничена пределами предстательной железы. Диагноз по результатам биопсии и послеоперационное морфологическое заключение совпадали в 86,7 % случаев.</p></sec><sec><title>Выводы</title><p>Выводы. Проведенное исследование показало, что сатурационная трансперинеальная биопсия является референсным методом диагностики в условиях, когда таргетная fusion-биопсия не дает возможности подтвердить или исключить рак предстательной железы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. One of the biggest problems in the diagnosis of prostate cancer (PCa), which distinguishes it from many other solid tumour conditions, is the difficulty of detecting the tumour using standard imaging techniques. The primary method of diagnosis of PCa, which allows timely treatment, is prostate biopsy. However, under certain clinical situations a saturation biopsy allows a more accurate prediction of the volume and degree of malignancy of the tumour, which can be used to plan the tactics of treatment.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 81 patients were examined, whose mean age was 63.5 ± 7.4. The average volume of the prostate was 59 ± 24.2 cm3 , while the average level of the prostate-specific antigen was 12.5 ± 8.9 ng/ml. All patients underwent at least one transrectal prostate biopsy. The average duration of the transperineal saturation biopsy of the prostate was 25.2 ± 7.4 minutes. The average number of biopsies was 25.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Based on the results of transperineal saturation biopsy, prostate cancer was detected in 34 patients (43.2 %). Adenocarcinoma was detected in all patients with confirmed malignant pathology. Gleason grading was 6 points in 22 (27.1 %) patients, 7 in 9 (9.9 %) and 8 in 4 (4.9 %). Aggressive tumour types (Gleason 7 and 8) corresponded to PIRADS 4 and 5. In PIRADS 2 and 3, 80 % and 50 %, respectively, manifested prostatic adenoma without malignant manifestation. Following radical prostatectomy, the results of a planned morphological conclusion were studied alongside biopsy data. It was determined that in 80.0 % (n = 12) of cases the tumour did not go beyond the prostate capsule and in only 20.0 % (n = 3) of cases was not confined to the prostate. The coincidence of diagnosis based on biopsy results and morphological conclusion was 86.7 %.</p></sec><sec><title>Conclusion</title><p>Conclusion. The study showed that saturation transperineal biopsy is often a reference diagnostic method when, despite the presence of clinical suspicion of PCa, a standard biopsy, including targeted fusion biopsies, fails to provide sufficient information to confirm or exclude PCa. In such situations, the proposed technique provides an alternative approach, with a good frequency of detection of prostate cancer.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>новообразования предстательной железы</kwd><kwd>биопсия</kwd><kwd>сатурационная биопсия</kwd><kwd>трансперинеальная биопсия</kwd><kwd>таргетная fusion-биопсия</kwd><kwd>аденокарцинома</kwd><kwd>простатэктомия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prostatic neoplasms</kwd><kwd>biopsy</kwd><kwd>saturation biopsy</kwd><kwd>transperineal biopsy</kwd><kwd>targeted fusion biopsy</kwd><kwd>adenocarcinoma</kwd><kwd>prostatectomy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2017 году. М.: ФГБУ «МНИОИ им П.А. Герцена», 2018.</mixed-citation><mixed-citation xml:lang="en">Caprin A.D., Starinskiy V.V., Petrova G.V. (eds) Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: MNIOI them. P.A. Herzen is a branch of the Federal Medical and Biological Center NIIRTs of the Russian Ministry of Health, 2018. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Зырянов А.В., Федоров Н.М., Зотов П.Б., Налетов А.А., Бурханова Л.А., Смирнов В.О. и др. Заболеваемость и смертность от злокачественных новообразований населения Тюменской области в 2017 г. Тюменский медицинский журнал. 2017;19(2):55–9.</mixed-citation><mixed-citation xml:lang="en">Zyryanov A.V., Fedorov N.M., Zotov P.B., Naletov A.A., Burkhanova L.A., Smirnov V.O., et al. Morbidity and mortality from malignant neoplasms of the population of the Tyumen region in 2017. Tyumen Medical Journal. 2017;19(2):55–9. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. DOI: 10.3322/caac.20138</mixed-citation><mixed-citation xml:lang="en">Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. DOI: 10.3322/caac.20138</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bjurlin M.A., Wysock J.S., Taneja S.S. Optimization of prostate biopsy: review of technique and complications. Urol Clin North Am. 2014;41(2):299–313. DOI: 10.1016/j.ucl.2014.01.011. PMID: 24725491.</mixed-citation><mixed-citation xml:lang="en">Bjurlin M.A., Wysock J.S., Taneja S.S. Optimization of prostate biopsy: review of technique and complications. Urol Clin North Am. 2014;41(2):299–313. DOI: 10.1016/j.ucl.2014.01.011. PMID: 24725491.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Кельн А.А., Лыков А.В., Сальников М.А. PSA-скрининг в Тюменской области. Тюменский медицинский журнал. 2014;16(4):25–6.</mixed-citation><mixed-citation xml:lang="en">Keln A.A., Lykov A.V., Salnikov M.A. PSA-screening in the Tyumen region. Tyumen Medical Journal. 2014;16(4):25–6. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cash H., Maxeiner A., Stephan C., Fischer T., Durmus T., Holzmann J., et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/ transrectal ultrasound fusion biopsy. World J Urol. 2016;34(4):525–32. DOI: 10.1007/s00345-015-1671-8. PMID: 26293117.</mixed-citation><mixed-citation xml:lang="en">Cash H., Maxeiner A., Stephan C., Fischer T., Durmus T., Holzmann J., et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/ transrectal ultrasound fusion biopsy. World J Urol. 2016;34(4):525–32. DOI: 10.1007/s00345-015-1671-8. PMID: 26293117.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кельн А.А., Зырянов А.В., Суриков А.С., Пономарев А.В., Купчин А.В. Первый опыт совмещенной МРТ-ТРУЗИ биопсии предстательной железы. Медицинский вестник Башкортостана. 2017;12(3):91–4.</mixed-citation><mixed-citation xml:lang="en">Keln A.A., Zyryanov A.V., Surikov A.S., Ponomarev A.V., Kupchin A.V. The first experience of mri-trus fusion biopsy of the prostate. Medical bulletin of Bashkortostan. 2017;12(3):91–4. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Maccagnano C., Gallina A., Roscigno M., Raber M., Capitanio U., Saccà A., et al. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int. 2012;89:126–35. DOI: 10.1159/000339521</mixed-citation><mixed-citation xml:lang="en">Maccagnano C., Gallina A., Roscigno M., Raber M., Capitanio U., Saccà A., et al. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int. 2012;89:126–35. DOI: 10.1159/000339521</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kammerer-Jacquet S.F., Compérat E., Egevad L., Hes O., Oxley J., Varma M., et al. Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP). Virchows Arch. 2018;472(4):599–604. DOI: 10.1007/s00428-017-2265-1</mixed-citation><mixed-citation xml:lang="en">Kammerer-Jacquet S.F., Compérat E., Egevad L., Hes O., Oxley J., Varma M., et al. Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP). Virchows Arch. 2018;472(4):599–604. DOI: 10.1007/s00428-017-2265-1</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Srirangam V., Rai B.P., Abroaf A., Agarwal S., Tadtayev S., Foley C., et al. Atypical small acinar proliferation and high grade prostatic intraepithelial neoplasia: should we be concerned? An observational cohort study with a minimum follow-up of 3 years. Curr Urol. 2017;10(4):199–205. DOI: 10.1159/000447181</mixed-citation><mixed-citation xml:lang="en">Srirangam V., Rai B.P., Abroaf A., Agarwal S., Tadtayev S., Foley C., et al. Atypical small acinar proliferation and high grade prostatic intraepithelial neoplasia: should we be concerned? An observational cohort study with a minimum follow-up of 3 years. Curr Urol. 2017;10(4):199–205. DOI: 10.1159/000447181</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cui K., Li X., Du Y., Tang X., Arai S., Geng Y., et al. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison. Oncotarget. 2017;8(22):36674–84. DOI: 10.18632/oncotarget.16230</mixed-citation><mixed-citation xml:lang="en">Cui K., Li X., Du Y., Tang X., Arai S., Geng Y., et al. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison. Oncotarget. 2017;8(22):36674–84. DOI: 10.18632/oncotarget.16230</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shah R.B., Leandro G., Romerocaces G., Bentley J., Yoon J., Mendrinos S., et al. Improvement of diagnostic agreement among pathologists in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies using a novel “Disease-Focused Diagnostic Review” quality improvement process. Hum Pathol. 2016;56:155–62. DOI: 10.1016/j.humpath.2016.06.009</mixed-citation><mixed-citation xml:lang="en">Shah R.B., Leandro G., Romerocaces G., Bentley J., Yoon J., Mendrinos S., et al. Improvement of diagnostic agreement among pathologists in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies using a novel “Disease-Focused Diagnostic Review” quality improvement process. Hum Pathol. 2016;56:155–62. DOI: 10.1016/j.humpath.2016.06.009</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jansen I., Lucas M., Savci-Heijink C.D., Meijer S.L., Marquering H.A., de Bruin D.M., et al. Histopathology: ditch the slides, because digital and 3D are on show. World J Urol. 2018;36(4):549–55. DOI: 10.1007/s00345-018-2202-1</mixed-citation><mixed-citation xml:lang="en">Jansen I., Lucas M., Savci-Heijink C.D., Meijer S.L., Marquering H.A., de Bruin D.M., et al. Histopathology: ditch the slides, because digital and 3D are on show. World J Urol. 2018;36(4):549–55. DOI: 10.1007/s00345-018-2202-1</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кельн А.А., Зырянов А.В., Суриков А.С., Пономарев А.В., Купчин А.В., Знобищев В.Г. и др. Fusion-биопсия предстательной железы у пациентов с ранее отрицательной биопсией в анамнезе. Вестник урологии. 2017;5(4):39–46. DOI: 10.21886/2308-6424-2017-5-4-39-46</mixed-citation><mixed-citation xml:lang="en">Keln A.A., Zyryanov A.V., Surikov A.S., Ponomarev A.V., Kupchin A.V., Znobischev V.G., et al. Fusion prostate biopsy in patients with previous negative standard prostate biopsy. Herald of urology. 2017;5(4):39–46. DOI: 10.21886/2308-6424-2017-5-4-39-46 (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mortezavi A., Märzendorfer O., Donati O.F., Rizzi G., Rupp N.J., Wettstein M.S., et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. J Urol. 2018;200(2):309–18. DOI: 10.1016/j.juro.2018.02.067</mixed-citation><mixed-citation xml:lang="en">Mortezavi A., Märzendorfer O., Donati O.F., Rizzi G., Rupp N.J., Wettstein M.S., et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. J Urol. 2018;200(2):309–18. DOI: 10.1016/j.juro.2018.02.067</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen N.L., Barrett T., Kesch C., Pepdjonovic L., Bonekamp D., O’Sullivan R., et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer. BJU Int. 2018;122(1):40–9. DOI: 10.1111/bju.14049</mixed-citation><mixed-citation xml:lang="en">Hansen N.L., Barrett T., Kesch C., Pepdjonovic L., Bonekamp D., O’Sullivan R., et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer. BJU Int. 2018;122(1):40–9. DOI: 10.1111/bju.14049</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bul M., Zhu X., Valdagni R., Pickles T., Kakehi Y., Rannikko A., et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63(4):597–603. DOI: 10.1016/j.eururo.2012.11.005</mixed-citation><mixed-citation xml:lang="en">Bul M., Zhu X., Valdagni R., Pickles T., Kakehi Y., Rannikko A., et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63(4):597–603. DOI: 10.1016/j.eururo.2012.11.005</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Emberton M. Why focal therapy is a legitimate and necessary response to a changing world. J Urol. 2015;194(4):875–6. DOI: 10.1016/j.juro.2015.07.049</mixed-citation><mixed-citation xml:lang="en">Emberton M. Why focal therapy is a legitimate and necessary response to a changing world. J Urol. 2015;194(4):875–6. DOI: 10.1016/j. juro.2015.07.049</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Baba K., Sekine Y., Miyazawa Y., Syuto T., Nomura M., Koike H., et al. Assessment of antimicrobiral prophylaxis in transperineal prostate biopsy: a single-center retrospective study of 485 cases. J Infect Chemother. 2018;24(8):637–40. DOI: 10.1016/j.jiac.2018.03.014</mixed-citation><mixed-citation xml:lang="en">Baba K., Sekine Y., Miyazawa Y., Syuto T., Nomura M., Koike H., et al. Assessment of antimicrobiral prophylaxis in transperineal prostate biopsy: a single-center retrospective study of 485 cases. J Infect Chemother. 2018;24(8):637–40. DOI: 10.1016/j.jiac.2018.03.014</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
